Microbubbles/Ultrasound Contrast Agents Market (2026-2036)

This report covers gas-filled microbubble contrast agents administered intravenously to enhance ultrasound imaging, together with their therapeutic applications, across lipid, protein and polymer shell chemistries, diagnostic imaging and therapeutic use, and the hospital, laboratory and other care settings in which they are administered. The growth of this market is driven by the reassignment of non-cardiac contrast-enhanced ultrasound to a higher hospital outpatient payment level from January 2026, by the suitability of these agents for patients in whom iodinated and gadolinium-based contrast cannot be used, by the absence of ionising radiation, and by the emergence of therapeutic microbubble applications in which the agent carries or enables a treatment rather than only an image.

The decisive constraint on this market has never been clinical evidence or product availability, and understanding that is the key to reading the forecast correctly. Approved agents have existed for decades, guideline support is settled across the major indications, and the clinical case in renal impairment and pregnancy is strong. What held adoption back in the largest national market was payment, because the hospital outpatient rate for a contrast-enhanced ultrasound study did not sit at the level paid for contrast-enhanced computed tomography or magnetic resonance imaging. That specific gap closed at the start of the forecast period, which is why the growth profile in this edition is weighted towards the non-cardiac diagnostic segment rather than spread evenly across the market.

A second structural feature belongs at the front of any assessment. The agent is inexpensive relative to the procedure it enables. At the published first quarter 2026 average sales prices, a Definity vial is USD 80.41 and a Lumason vial USD 90.83 against a hospital outpatient payment of USD 356.43 for the initial lesion study, so the consumable represents roughly a quarter of the facility payment. Growth in this market therefore follows procedure volume rather than agent pricing, and manufacturers compete on indication breadth, clinical support and supply reliability rather than on price per dose.

A microbubble contrast agent is a suspension of gas-filled spheres small enough to pass through the pulmonary circulation and remain within the vascular space. Because the bubbles resonate under an ultrasound field, they return a signal far stronger than tissue, which makes blood visible where it was previously inferred from motion alone. That physical behaviour explains both the clinical value of these agents and the shape of the market around them, because the agent is a consumable within a procedure performed on equipment that the provider already owns, and the economics of the market are therefore set by the economics of the procedure.

Shell chemistry divides the product. Lipid-shelled agents dominate clinical use because the shell is flexible enough to oscillate strongly at diagnostic pressures while remaining stable in circulation, which gives the combination of signal and persistence that imaging requires. Protein-shelled agents, built on human albumin, remain in use and hold established cardiac indications. Polymer-shelled agents are stiffer and less efficient as pure reflectors, which has limited their diagnostic role, but the same stiffness allows them to be loaded and to be ruptured in a controlled way, which is why they matter disproportionately in the therapeutic segment relative to their diagnostic share.

The commercial story of the last decade has been payment rather than science, and the position changed at the start of this forecast period. In August 2025 the Board of Directors of the International Contrast Ultrasound Society wrote to the Centers for Medicare and Medicaid Services asking that CPT 76978 and CPT 76979 be reassigned to ambulatory payment classification 5572, on the grounds that contrast-enhanced computed tomography and magnetic resonance imaging already sit there and that the reassignment would create a clinical coherency absent from the previous assignment. The society stated that it sought no change for cardiac contrast-enhanced ultrasound.

The 2026 position shows that request reflected in the payment chart. The 2026 coding and payment chart published by the International Contrast Ultrasound Society, effective 1 January 2026 and updated 1 February 2026, assigns CPT 76978, non-cardiac contrast-enhanced ultrasound for the initial lesion, to ambulatory payment classification 5572, Level 2 Imaging with Contrast, at USD 356.43 in the hospital outpatient setting. The practical effect is that a hospital performing a contrast-enhanced ultrasound study for an initial lesion is now paid within the same imaging-with-contrast classification family as the cross-sectional alternatives, which removes the structural disincentive that previously made the study financially unattractive relative to a contrast computed tomography scan. This is the single most consequential development for the non-cardiac segment in the forecast period, and the forecast in this report is weighted accordingly.

The agents remain separately payable, which matters because it means the provider is not absorbing the consumable within the procedure payment. The same chart shows the agents themselves remaining separately payable at average sales price in the first quarter of 2026, with Lumason under HCPCS Q9950 at USD 18.17 per millilitre and USD 90.83 for a 5 millilitre vial, Optison under Q9956 at USD 40.21 per millilitre and USD 120.61 for a 3 millilitre vial, and Definity under Q9957 at USD 40.21 per millilitre and USD 80.41 for a 2 millilitre vial.

Those figures also establish the proportionality that should govern any commercial assessment of this market. A Definity vial at USD 80.41 and a Lumason vial at USD 90.83 sit against a facility payment of USD 356.43 for the study, so the agent is approximately a quarter of the payment for the procedure it makes possible. The consequence is that agent price is not the lever on adoption, and a manufacturer pursuing volume through discounting is addressing the smaller part of the provider calculation. What moves volume is whether the study is paid properly, whether the indication is on label, and whether the radiologist or sonographer is trained and confident in the technique.

One residual payment constraint deserves stating because it shapes where studies are performed and how they are scoped. CPT 76979, covering each additional lesion, is packaged in the hospital outpatient setting and carries no separate payment, while in the non-facility setting it is payable as an add-on. A patient with several lesions therefore generates no additional facility payment for the additional characterisation work, which caps the economics of multi-lesion studies in the hospital outpatient setting and gives the office and independent diagnostic testing facility setting a relative advantage for those cases. Suppliers reading only the headline reassignment will miss this, and it is a live constraint on the segment that the reassignment was meant to open.

Evidence of underlying momentum is available from the one agent whose revenue is publicly reported. Lantheus Holdings reported first quarter 2026 results on 7 May 2026, recording sales of DEFINITY of USD 84.6 million, an increase of 6.8% against USD 79.2 million in the first quarter of 2025, within worldwide revenue of USD 377.3 million that grew 1.2% over the same period. Two observations follow. The agent franchise grew at several times the rate of the diversified imaging business that contains it, which indicates that growth is specific to contrast ultrasound rather than a general imaging trend. And the annualised figure implied by that quarter, approximately USD 338 million, represents close to thirty per cent of the global market estimated for 2026 in this report, which is a useful external check on the sizing and a reminder that this is a concentrated market in which three agents account for most of global consumption.

The clinical argument that sustains demand is narrower and more durable than general enthusiasm for ultrasound. Microbubble agents contain neither iodine nor gadolinium and are not nephrotoxic, which makes contrast-enhanced ultrasound the appropriate advanced imaging option for patients in whom contrast computed tomography and magnetic resonance imaging are contraindicated by renal impairment. They do not cross the placenta and the examination involves no ionising radiation, which extends the same logic to pregnancy. These are not marginal populations in a hospital practice, and because the alternative in these patients is frequently no advanced contrast imaging at all rather than a different modality, demand in this part of the market is substitution-resistant.

The therapeutic segment is where the long-term option value sits, and it should be assessed as a device-led opportunity rather than an agent-led one. Insightec announced on 9 March 2022 that the United States Food and Drug Administration had approved two pivotal investigational device exemptions for the Exablate Neuro system and had granted Breakthrough Device designation for the treatment of primary non-small cell lung cancer metastatic to the brain in conjunction with standard-of-care pembrolizumab, under the LIMITLESS study. The second exemption covers enhanced efficacy of liquid biopsy for recurrence monitoring in primary brain cancer. The principal investigator described low-intensity focused ultrasound with microbubbles opening the blood brain barrier, and the release stated that low-intensity focused ultrasound can transiently increase the permeability of the blood brain barrier and allow passage of region-specific biomarkers.

The mechanism matters more than any single programme. Microbubbles under a focused ultrasound field transiently open the blood brain barrier, which allows a systemically administered drug to reach the brain and allows biomarkers to leave it. Both directions have been taken into pivotal study, the first for drug delivery alongside immunotherapy and the second as a non-invasive alternative to neurosurgical biopsy. The commercial caution is that in these applications the microbubble is a low-cost consumable within a high-cost procedure delivered on capital equipment, so success transforms procedure volumes and device revenue far more than it transforms agent revenue. The therapeutic segment therefore grows fastest in percentage terms from a small base, and a forecast that treats therapeutic promise as agent revenue will overstate this market substantially.

Supply concentration is the risk that does not appear in the clinical literature. Three agents account for most global consumption, each manufactured by a single company, and at least one manufacturer identifies its ability to produce the agent in its own facility in the amounts and at the times needed as a recognised risk. For a provider, a contrast-enhanced ultrasound service built around a single agent is a service exposed to that agent supply. For a manufacturer, reliability of supply is accordingly a competitive attribute rather than an operational detail, and it is one of the few grounds on which a second agent can displace an incumbent in an established department.